GLP-1 agonist

Lilly steps up its oral obesity push
Lilly steps up its oral obesity push
EP Vantage
Eli Lilly
obesity
GLP-1 agonist
orforglipron
Flag link:
Study: Type 2 Diabetes Treatments May Be More Effective When Combined
Study: Type 2 Diabetes Treatments May Be More Effective When Combined
BioSpace
diabetes
type 2 diabetes
FGF21
GLP-1 agonist
Flag link:
Highlights: 2019 Cardiometabolic Health Congress, Chicago IL
Highlights: 2019 Cardiometabolic Health Congress, Chicago IL
CP Wire
cardiometabolic health
GLP-1 agonist
diabetes
lipids
hypertension
chronic kidney disease
heart failure
obesity
Flag link:
Highlights: 2019 Cardiometabolic Health Congress, Chicago IL
cardiometabolic health
GLP-1 agonist
diabetes
lipids
hypertension
chronic kidney disease
heart failure
obesity
Flag link:
Repurposing a GLP-1 diabetes drug to slow Parkinson’s disease
Repurposing a GLP-1 diabetes drug to slow Parkinson’s disease
Fierce Biotech
diabetes
Parkinson's Disease
GLP-1 agonist
AstraZeneca
Byetta
Bydureon
Novo Nordisk
Victoza
Ozempic
Eli Lilly
Trulicity
Peptron
Flag link:
Novo Nordisk results show GLP-1s are job 1. Can its crucial Ozempic launch deliver?
Novo Nordisk results show GLP-1s are job 1. Can its crucial Ozempic launch deliver?
Fierce Pharma
Novo Nordisk
GLP-1 agonist
diabetes
Ozempic
drug launches
Flag link:
GI toxicity hits midstage Sanofi GLP-1 drug as patients drop out
GI toxicity hits midstage Sanofi GLP-1 drug as patients drop out
Fierce Biotech
Sanofi
clinical trials
GLP-1 agonist
SAR425899
Flag link:
GLP-1 Drug Class May Continue to Drive Growth for Novo Nordisk
GLP-1 Drug Class May Continue to Drive Growth for Novo Nordisk
Market Realist
Novo Nordisk
GLP-1 agonist
diabetes
Victoza
Flag link:
GlaxoSmithKline GLP-1 Tanzeum meets its end, and it doesn't bode well for Sanofi, AstraZeneca: analyst
GlaxoSmithKline GLP-1 Tanzeum meets its end, and it doesn't bode well for Sanofi, AstraZeneca: analyst
Fierce Pharma
GSK
GLP-1 agonist
Tanzeum
Sanofi
AstraZeneca
Flag link:
New Novo Nordisk Strategy Drops Oral Insulin, Expands Oral GLP-1
New Novo Nordisk Strategy Drops Oral Insulin, Expands Oral GLP-1
Seeking Alpha
Novo Nordisk
diabetes
oral insulin
insulin
GLP-1 agonist
R&D
Flag link:
Sanofi Should Be Thinking Longer Duration In GLP-1s
Sanofi Should Be Thinking Longer Duration In GLP-1s
Seeking Alpha
Sanofi
GLP-1 agonist
Adlyxin
Flag link:
Diabetes sales rocket toward $60B, with Novo and Lilly's GLP-1s first in line for growth
Diabetes sales rocket toward $60B, with Novo and Lilly's GLP-1s first in line for growth
Fierce Pharma
diabetes
Novo Nordisk
Eli Lilly
GLP-1 agonist
Victoza
Trulicity
Flag link:
Novo Nordisk notches another phase 3 success for GLP-1 drug
Novo Nordisk notches another phase 3 success for GLP-1 drug
BioPharma Dive
Novo Nordisk
diabetes
GLP-1 agonist
semaglutide
Flag link:
Novo Nordisk's First Diabetes Pill Could Be A $10-20 Billion Super-Blockbuster
Novo Nordisk's First Diabetes Pill Could Be A $10-20 Billion Super-Blockbuster
Seeking Alpha
Novo Nordisk
diabetes
semaglutide
GLP-1 agonist
Flag link:
Sanofi, Hanmi seal diabetes license deal for up to $4.2 bln
Sanofi, Hanmi seal diabetes license deal for up to $4.2 bln
Yahoo/Reuters
Sanofi
Hanmi Pharma
diabetes
GLP-1 agonist
South Korea
Flag link:
Victoza tops Sanofi's Lyxumia in trial, adding to Novo's GLP-1 arsenal
Victoza tops Sanofi's Lyxumia in trial, adding to Novo's GLP-1 arsenal
Fierce Pharma
Victoza
Lyxumia
Novo Nordisk
Sanofi
diabetes
GLP-1 agonist
Flag link:
Novo jumping into phase III trials for major oral diabetes candidate
Novo jumping into phase III trials for major oral diabetes candidate
BioPharma Dive
Novo Nordisk
diabetes
semaglutide
GLP-1 agonist
Flag link:
Novo Nordisk looks past blockbuster Victoza with PhIII success for weekly GLP-1 med
Novo Nordisk looks past blockbuster Victoza with PhIII success for weekly GLP-1 med
Fierce Pharma Marketing
Novo Nordisk
diabetes
Victoza
semaglutide
GLP-1 agonist
Flag link:
Novo Nordisk's new GLP-1 diabetes drug hits goal in trial
Novo Nordisk's new GLP-1 diabetes drug hits goal in trial
Yahoo/Reuters
Novo Nordisk
GLP-1 agonist
diabetes
semaglutide
Flag link:
Expect Novo Nordisk To Commit To Their Late-Stage Diabetes Pill Development Soon
Expect Novo Nordisk To Commit To Their Late-Stage Diabetes Pill Development Soon
Seeking Alpha
Novo Nordisk
GLP-1 agonist
diabetes
Flag link:

Pages